Upon ingestion, the new Enzian dosage form resides in the stomach for several hours and steadily delivers drug into the blood. This enables enhanced effectiveness of many life-saving drug therapies.

ZÜRICH, June 30, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (NASDAQ: NLSP) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on developing therapies for central ...

NLS Pharmaceutics (NASDAQ:NLSP) rose in premarket trading on Monday after the company reported a definitive merger agreement with Kadimastem. NLSP (NLSP) stock climbed +57.22% to $5.66 +2.06 premarket ...

Pharmaceutics International, Inc. (Pii), a contract development and manufacturing organization (CDMO), today announced the formation of a new leadership team whose strengths and dedication to ...

(RTTNews) - NLS Pharmaceutics AG (NLSP) and Kadimastem Ltd. (KDST.TA), which announced their plan to form a combined Nasdaq-listed biotechnology company last month, have today introduced a new ...

NLS Pharmaceutics (NLSP) provided insights into the preclinical program evaluating its dual orexin receptor agonist platform. AEX-41 and AEX-2, two first-in-class non-sulfonamide DOXAs, are designed ...

Molecular Pharmaceutics is a peer-reviewed scientific journal, published since 2004 by the American Chemical Society. MP is currently indexed in: Chemical Abstracts Service (CAS), SCOPUS, EBSCOhost, ...

For more than a century, oral insulin has been considered a "dream" therapy for diabetes, hindered by enzymatic degradation ...